
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Philadelphia - Atopic dermatitis is a chronic or chronically recurring, usually pruritic and clinically variable skin disease associated with atopy.